NCT02426099

Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension

Prevalence and Treatment of Resistant Hypertension in Diabetic Patients in Yaounde

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Sobngwi Eugene · Other Government
• Sex: All
• Age: 21 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a four-week randomized controlled single blinded trial of subjects presenting with resistant hypertension in a specialized diabetes care unit of Cameroon. They are randomly assigned using the method of blocks to treatment with a daily 25mg of spironolactone or to routine intensification of antihypertensive regimen , all added to previous regimen with unchanged diet. Visits are scheduled at the start of the treatment, at weeks two and four following add-on therapy initiation. The primary outcome is change in office and self-measurement blood pressure recorded at each visit, and secondary outcomes are variations in serum potassium, sodium, and creatinine levels.

Conditions

• Hypertension, Resistant to Conventional Therapy
• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Low dose spironolactone	4-week add-on low dose spironolactone in resistant hypertension
OTHER	Routine intensification of antihypertensive treatment	4-week guidelines oriented intensification of antihypertensive treatment

Timeline

• Start date: 2011-10-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2015-04-24
• Last updated: 2015-04-24

Locations

1 site across 1 country: Cameroon